In vitro and in vivo effects of HIV protease inhibitors on apoptosis

Cell Death and Differentiation

Volumn 12, Issue , 2005, Pages 924-931

  Badley, A D ^a  

^a Mayo Clinic   (United States)

Author keywords

Cd4; Hiv; Proteases

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CALPAIN; CASPASE; INDINAVIR; INTERLEUKIN 2; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RALOXIFENE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; APOPTOSIS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFECT; ENZYME INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; MEMBRANE POTENTIAL; MITOCHONDRION; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS MUTATION; VIRUS REPLICATION;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOPTOSIS; CALPAIN; CASPASES; CD4-CD8 RATIO; CELL PROLIFERATION; HIV INFECTIONS; HIV PROTEASE; HUMANS; MITOCHONDRIA; PROTEASE INHIBITORS;

EID: 22744437219     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401580     Document Type: Review

References (58)

1. Strack PR, Frey MW, Rizzo CJ, Cordova B, George HJ, Meade R, Ho SP, Corman J, Tritch R and Korant BD (1996) Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. Proc. Natl. Acad. Sci. USA 93: 9571-9576
2. Korant BD, Strack PR, Frey MW and Rizzo CJ (1998) A cellular anti-apoptosis protein is cleaved by the HIV-1 protease. Adv. Exp. Med. Biol. 436: 27-29
3. Shoeman RL, Honer B, Stoller TJ, Kesselmeier C, Miedel MC, Traub P and Graves MC (1990) Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. Proc. Natl. Acad. Sci. USA 87: 6336-6340
4. Tomasselli AG, Hui JO, Adams L, Chosay J, Lowery D, Greenberg B, Yem A, Deibel MR, Zurcher-Neely H and Heinrikson RL (1991) Actin, Troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1-beta as substrates of the protease from human immunodeficiency virus. J. Biol. Chem. 266: 14548-14553
5. Adams LD, Tomasselli AG, Robbins P, Moss B and Heinrikson RL (1992) HIV- 1 protease cleaves actin during acute infection of human T-lymphocytes. AIDS Res. Hum. Retroviruses 8: 291-295
6. Shoeman RL, Sachse C, Honer B, Mothes E, Kaufmann M and Traub P (1993) Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodeficiency virus type 1 protease. Actin, desmin, myosin, and tropomyosin. Am. J. Pathol. 142: 221-230
7. Shoeman RL, Huttermann C, Hartig R and Traub P (2001) Amino-terminal polypeptides of vimentin are responsible for the changes in nuclear architecture associated with human immunodeficiency virus type 1 protease activity in tissue culture cells. Mol. Biol. Cell. 12: 143-154
8. Ohlmann T, Prevot D, Decimo D, Roux F, Garin J, Morley SJ and Darlix J-L (2002) In vitro cleavage of eIF4GI but not eIF4GII by HIV-1 protease and its effects on translation in the rabbit reticulocyte lysage system. J. Mol. Biol. 318: 9-20
9. Shoeman RL, Hartig R, Hauses C and Traub P (2002) Organization of focal adhesion plaques is disrupted by action of the HIV-1 protease. Cell. Biol. Int. 26: 529-539
10. Ventoso I, Blanco R, Perales C and Carrasco L (2001) HIV-1 protease cleaves eukaryotic initiation factor 4G and inhibits cap-dependent translation. Proc. Natl. Acad. Sci. USA 98: 12966-12971
11. Perales C, Carrasco L and Ventoso I (2003) Cleavage of eIF4G by HIV-1 protease: effects on translation. FEBS Lett. 533: 89-94
12. Nie Z, Phenix BN, Lum J, Alam A, Lynch DH, Beckett B, Krammer PH, Sekaly RF and Badley AD (2002) HIV-1 protease processes procaspase 8 to cause mitochondrial release of chtychrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ. 9: 1172-1184
13. Petit F, Arnoult D, Viollet L and Estaquier J (2003) Intrinsic and extrinsic pathways signaling during HIV-1 mediated cell death. Biochimie 85: 795-811
14. Mohri H, Perelson AS, Tung K, Ribeiro RM, Ramratnam B, Markowitz M, Kost R, Hurley A, Weinberger L, Cesar D, Hellerstein MK and Ho DD (2001) Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J. Exp. Med. 194: 1277-1287
15. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA, Sereti I, Polis MA, Davey RT, Tavel J, Falloon J, Stevens R, Lambert L, Dewar R, Schwartzentruber DJ, Anver MR, Baseler MW, Masur H, Dimitrov DS and Lane HC (2001) Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J. Exp. Med. 194: 1731-1741
16. Lempicki RA, Kovacs JA, Baseler MW, Adelsberger JW, Dewar R, Natarajan V, Bosche MC, Metcalf JA, Stevens R, Lambert LA, Alvord WG, Polis MA, Davey RT, Dimitrov DS and Lane HC (2000) Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proc. Natl. Acad. Sci. USA 97: 13778-13783
17. Phenix BN, Cooper C, Owen C and Badley AD (2002) Modulation of apoptotis by HIV protease inhibitors. Apoptosis 7: 295-312
18. Gougeon M-L (2003) Apoptosis as an HIV stretegy to escape immune attack. Nat. Rev. Immunol. 3: 392-404
19. Badley AD, Pilon AA, Landay A and Lynch DH (2000) Mechanisms of HIV associated lymphocyte apoptosis. Blood 96: 2951-2964
20. Swiss HIV Cohort Study (2004) Persistent apoptosis in HIV-1-infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T lymphocytes. J. Acq. Immu. Def. Synd. 36: 671-677
21. Wasmuth JC, Hackbarth F, Rockstroh JK, Sauerbruch T and Spengler U (2003) Changes of lymphocyte apoptosis associated with sequential introduction of highly active antiretroviral therapy. HIV Med. 4: 111-119
22. Kravcik S, Magill A, Sanghvi B, Ogden R, Cameron DW, Lewis R, Yu G and Badley AD (2001) Comparative CD4 T cell responses of protease inhibitor containing and sparing antiretroviral regimens. HIV Clin. Trials 2: 160-170
23. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM and Study 006 Team (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New Engl. J. Med. 341: 1865-1873
24. Meroni L, Varchetta S, Manganaro D, Gatti N, Riva A, Mondorte A and Galli M (2002) Reduced levels of CD4 cell spontaneous apoptosis in human immundeficiency virus-infected patients with discordant response to protease inhibitors. J. Infect. Dis. 186: 143-144
25. Lecossier D, Bouchonnet F, Schneider P, Clavel F and Hance AJ Centre de Recherche Integre sur le VIH Bichat-Claude Bernard. (2001) Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J. Infect. Dis. 183: 1009-1016
26. Carr A, Emery S, Kelleher A, Law M and Cooper DA. (1996) CD8+ lymphocyte responses to antiretroviral therapy of HIV infection. J Acq. Immun. Def. Synd. 13: 320-326
27. Owen C, Kazim F and Badley AD (2004) Effect on CD4 T cell count of replacing protease inhibitors in patients with successful HIV suppression: a metaanalysis. AIDS 18: 693-695
28. Badley AD, Parato K, Cameron DW, Kravcik S, Phenix BN, Ashby D, Kumar A, Lynch DH, Tschopp J and Angel JB (1999) Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ. 6: 420-432
29. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Barugh A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L and AIDS Clinical Trials Group (1996) Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. New Engl. J. Med. 334: 1011-1017
30. Hirsch M, Steigbigel R, Staszewski S, Mellors J, Scerpella E, Hirschel B, Lange J, Squires K, Rawlins S, Meibohm A, Leavitt R and Protocol 039 Study Group (1999) A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J. Infect. Dis. 180: 659-665
31. Lu W and Andrieu J-M (2000) HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. Blood 96: 250-258
32. Landay AL, Spritzler J, Kessler H, Mildvan D, Pu M, Fox L, O’Neil D, Schock B, Kuritzkes D, Lederman MM and Group ACT (2003) Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor or protease inhibitorcontaining antiretroviral regimen. J. Infect. Dis. 188: 1444-1454
33. Sloand EM, Maciejewski J, Kumar P, Kim S, Chaudhuri A and Young N (2000) Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells. Blood 96: 2735-2739
34. Sloand EM, Young NS, Sato T, Kim S and Maciejewski JP (1998) Inhibition of interleukin-1 beta-converting enzyme in human hematopoietic progenitor cells results in blockade of cytokine-mediated apoptosis and expansion of their proliferative potential. Exp. Hematol. 26: 1093-1099
35. Sloand EM, Kumar PN, Kim S, Chaudhuri A, Weichold FF and Young NS (1999) Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 94: 1021-1027
36. Estaquier J, Lelievre J-D, Petit F, Brunner T, Moutouh-de Parseval L, Richman DD, Ameisen JC and Corbeil J (2002) Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4+ T-cell death. J. Virol. 76: 5966-5973
37. Phenix BN, Lum JJ, Nie Z, Sanchez-Dardon J and Badley AD. (2001) Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 98: 1078-1085
38. Matarrese P, Gambardella L, Cassone A, Vella S, Cauda R and Malorni W. (2003) Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. J. Immunol. 170: 6006-6015
39. Weichold FF, Bryant JL, Pati S, Barabitskaya O, Gallo RC and Reitz MSJ. (1999) HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J. Hum. Virol. 2: 261-269
40. Ghibelli L, Mengoni F, Lichtner M, Coppola S, De Nicola M, Bergamaschi A, Mastroianni C and Vullo V (2003) Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain. Biochem. Pharmacol. 66: 1505-1512
41. Chavan S, Kodoth S, Pahwa R and Pahwa S (2001) The HIV protease inhibitor indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood 98: 383-389
42. Andre P, Groettrup M, Klenerman P, De Guili R, Booth BLJ, Cerundolo V, Bonneville M, Jotereau F, Zinkernagel RM and Lotteau V (1998) An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. USA 95: 13120-13124
43. Vanderklish PW and Bahr BA. (2000) The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int. J. Exp. Pathol. 81: 323-339
44. Suzuki K, Hata S, Kawabata Y and Sorimachi H (2004) Structure, activation, and biology of calpain. Diabetes 53 (Suppl. 1): S12-S18
45. Cuerrier D, Nie Z, Badley AD and Davies PL (2005) Ritonavir does not inhibit calpain in vitro. Biochem. Biophys. Res. Commun. 327: 208-211
46. Wan W and DePetrillo PB (2002) Ritonavir inhibition of calcium-activated neutral proteases. Biochem. Pharmacol. 63: 1481-1484
47. Barker E, Kahn J, Fujimura S and Levy JA (1998) Protease inhibitors do not increase the CD4+ cell count in HIV-uninfected individuals. AIDS 12: 1117-1118
48. Cooper CL, Phenix BN, Mbisa G, Lum JJ, Parato K, Nawley N and Angel JB andBadley AD. (2004) Antiretroviral therapy influences cellular susceptibility to apoptosis in vivo. Frontiers Biosci. 9: 338-341
49. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG and Karl IE. (1999) Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 27: 1230-1251
50. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Xanthoudakis S, Roy S, Black C, Grimm E, Aspiotis R, Han Y, Nicholson DW and Karl IE. (2000) Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat. Immunol. 1: 496-501
51. Weaver JGR, Rouse MS and Steckelberg JM andBadley AD. (2004) Improved survival in experimental sepsis with an orally administered inhivitor of apoptosis. FASEB J. 18: 1185-1191
52. Orlowski RZ (1999) The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ. 6: 303-313
53. Gaedicke S, Firat-Geier E, Constantiniu O, Lucchiari-Hartz M, Freudenberg M, Galanos C and Niedermann G (2002) Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res. 62: 6901-6908
54. Sekiguchi T and Hunter T (1998) Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells. Oncogene 16: 369-380
55. Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, Morel P, Danne O and Calvo F (1998) Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s sarcoma. AIDS 12: F45-F49
56. Pati S, Pelser CB, Dufraine J, Bryant JL, Reitz MSJ and Weichold FF (2002) Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99: 3771-3779
57. Kim IY, Seong DH, Kim B-C, Lee DK, Remaley AT, Leach F, Morton RA and Kim S-J (2002) Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Res. 62: 3649-3653
58. Levenson AS, Svoboda KM, Pease KM, Kaiser SA, Chen B, Simons LA, Jovanovic BD, Dyck PA and Jordan VC (2002) Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 62: 4419-4426